Vaishali Sanchorawala MD
Professor, Hematology & Medical Oncology
Associate Director, Amyloidosis Center
72 E. Concord Street | (617) 358-4750
Hematology & Medical Oncology
BU-BMC Cancer Center
72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)
Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.
Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Chobanian and Avedisian School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.
Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.
Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.
She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.
Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.
Boston Medical Center Provider Profile
MBBS, Seth G.S. Medical College, 1988
Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684. PMID: 36546447.Published on 5/4/2023
Mendelson L, Prokaeva T, Lau KHV, Sanchorawala V, McCausland K, Spencer B, Dasari S, McPhail ED, Kaku MC. Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions. Amyloid. 2023 May 04; 1-7. PMID: 37140928.Published on 4/18/2023
Nau A, Shen Y, Sanchorawala V, Prokaeva T, Morgan GJ. Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data. Front Immunol. 2023; 14:1167235. PMID: 37143670.Published on 2/28/2023
Sanchorawala V. Eureka Moment-Innovation Comes of an Age in Light Chain Amyloidosis. JCO Oncol Pract. 2023 May; 19(5):276-277. PMID: 36854072.Published on 2/14/2023
Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, Suzuki K, Dispenzieri A, Merlini G, Comenzo RL, Cherepanov D, Hayden VC, Kumar A, Labotka R, Faller DV, Kastritis E. Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice. Am J Hematol. 2023 May; 98(5):720-729. PMID: 36708469.Published on 1/31/2023
Staron A, Mendelson LM, Joshi T, Ruberg FL, Sanchorawala V. Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre. Amyloid. 2023 Jan 31; 1-6. PMID: 36718932.Published on 1/23/2023
Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 Mar 21; 81(11):1076-1126. PMID: 36697326.Published on 1/4/2023
Verma K, Zhang T, Mueller D, Li J, Sanchorawala V, Staron A. Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report. Diagn Pathol. 2023 Jan 04; 18(1):1. PMID: 36597112.Published on 12/1/2022
Wechalekar AD, Sanchorawala V. Daratumumab in AL amyloidosis. Blood. 2022 Dec 01; 140(22):2317-2322. PMID: 35507692.Published on 10/10/2022
Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Geyer SM, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Witteles R, Sanchorawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. J Clin Oncol. 2023 Mar 01; 41(7):1393-1403. PMID: 36215675.
Published on 9/22/2022
There’s New Proof Crispr Can Edit Genes Inside Human Bodies
Published on 8/5/2022
Young Black Patients With AML Face Significantly Worse Outcomes
Published on 7/20/2022
Stem Cell Transplantation Shows Promise in AL Amyloidosis
Published on 7/14/2022
Stem cell transplantation produces prolonged survival with improved safety in patients with AL amyloidosis
Published on 7/14/2022
Stem cell transplantation for AL amyloidosis leads to long-term survival and possible cure in selected patients
Published on 9/10/2021
Dr. Sanchorawala on the Impact of Depth of Renal and Cardiac Response on Survival in AL Amyloidosis
Published on 3/25/2021
Honoring 20 Outstanding Women, Woman of the Year 2021 and Lifetime Achievement Award Video Released
Published on 2/24/2021
Vaishali Sanchorawala: Her Pioneering Research Into the Rare Disease Amyloidosis Defines the Field
Published on 9/3/2020
18th Annual Woman of the Year Awards Gala Postponed Until Next Spring: April 30
Published on 2/4/2020
Daratumumab Safe And Effective Option For Treating Light Chain (AL) AmyloidosisView full list of 10 media mentions.